GlassScriptPhysician profile
Maria E Cabanillas
NPI 1710071204
$37,739.47
in general payments reported to CMS, 2019-2025
10 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,471 · 2021: $21K · 2022: $6,768 · 2023: $2,438 · 2024: $3,037 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,320 · Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,320.00 |
| Food and Beverage | $600.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $18,818.05 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $11,620.13 | 2019-2022 | |
| Eli Lilly and Company | $3,150.00 | 2021 | |
| Novartis Pharma Ag | $2,750.00 | 2024 | Mekinist |
| Novartis Pharmaceuticals Corporation | $1,000.00 | 2023 | |
| Eisai INC. | $142.20 | 2019-2025 | |
| Horizon Therapeutics Plc | $117.86 | 2023 | Tepezza |
| Jazz Pharmaceuticals INC. | $112.78 | 2024 | |
| Ascendis Pharma Endocrinology INC | $28.45 | 2025 | Yorvipath |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Cabanillas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.